Cargando…
Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/ https://www.ncbi.nlm.nih.gov/pubmed/36430959 http://dx.doi.org/10.3390/ijms232214481 |
_version_ | 1784838422740860928 |
---|---|
author | Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong |
author_facet | Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong |
author_sort | Piao, Xuan-Mei |
collection | PubMed |
description | To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment. |
format | Online Article Text |
id | pubmed-9696895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96968952022-11-26 Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong Int J Mol Sci Article To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment. MDPI 2022-11-21 /pmc/articles/PMC9696895/ /pubmed/36430959 http://dx.doi.org/10.3390/ijms232214481 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title_full | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title_fullStr | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title_full_unstemmed | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title_short | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
title_sort | utility of a molecular signature for predicting recurrence and progression in non-muscle-invasive bladder cancer patients: comparison with the eortc, cueto and 2021 eau risk groups |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/ https://www.ncbi.nlm.nih.gov/pubmed/36430959 http://dx.doi.org/10.3390/ijms232214481 |
work_keys_str_mv | AT piaoxuanmei utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT kimseonkyu utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT byunyoungjoon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT zhengchuangming utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT kanghowon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT kimwontae utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT kimyongjune utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT leesangcheol utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT kimwunjae utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT moonsungkwon utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT choiyunghyun utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups AT yunseokjoong utilityofamolecularsignatureforpredictingrecurrenceandprogressioninnonmuscleinvasivebladdercancerpatientscomparisonwiththeeortccuetoand2021eauriskgroups |